Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The supplied evaluation content states that the referenced boxed-warning topics (increased mortality in elderly patients with dementia-related psychosis; suicidality/monitoring language with antidepressants) are supported by the provided ABILIFY label excerpts (5.1, 5.2, 5.3, 17, 5.14) with no contradictions or material omissions identified within the provided text.
Category Scores
Accurate Statements
Boxed warning/related warnings: Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at increased risk of death; ABILIFY is not approved for treatment of dementia-related psychosis.
Supported by provided label excerpts in 5.1 and 5.2.
Suicidal thoughts and behaviors/monitoring language: Antidepressants increased risk of suicidal thoughts/behavior in children, adolescents, and young adults, with monitoring/close observation and caregiver/family alerting; close supervision of high-risk patients is recommended.
Supported by provided label excerpts in 5.3, 17, and 5.14.
Unsupported Statements
Contradictions
Important Omissions
No evaluation of other boxed warnings/label warnings beyond the two topics referenced (e.g., any additional precautions not included in the provided excerpts).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The response limits evaluation to label-supported boxed-warning topics and matches the provided label language without contradictions.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Scope limited to the referenced boxed-warning topics; other label sections are not assessed.
Suggested Improvement
If a broader label compliance review is needed, evaluate additional relevant sections beyond 5.1/5.2 and 5.3/17/5.14 using the full supplied prescribing information.